Clinical Effectiveness in Dravet Syndrome
Stiripentol shows seizure reduction comparable to fenfluramine in Dravet syndrome patients. In a phase 3 trial, stiripentol added to clobazam and valproate cut monthly convulsive seizures by 54% versus 19% with placebo.[1] Fenfluramine, in separate trials, reduced seizures by 54-68% over placebo when added to standard therapy.[2][3] Head-to-head data is absent, but both rank similarly in network meta-analyses for efficacy.[4]
How Do Side Effects Compare?
Stiripentol has lower cardiac risk—no echocardiogram monitoring required—unlike fenfluramine, which demands regular heart checks due to rare valvular and pulmonary hypertension risks (0.4-2% incidence in trials).[5][6] Stiripentol's main issues are sedation, appetite loss, and elevated liver enzymes, often manageable by reducing clobazam dose.[1] Fenfluramine causes more weight loss (up to 10% body weight) and decreased appetite.[2]
Dosing and Administration Differences
Stiripentol needs powder mixed with food or liquid, taken three times daily, and works only with clobazam.[1] Fenfluramine offers oral solution or tablet, dosed once or twice daily, without clobazam dependency, suiting broader regimens.[3]
Who Approves These for Kids?
Both are FDA-approved for Dravet syndrome in ages 2+. Stiripentol (Diacomit) suits clobazam users; fenfluramine (Fintepla) fits others. EMA approvals align similarly.[5][6]
Cost and Access Factors
Fenfluramine lists at $1,200-$1,500 monthly (U.S. cash price), stiripentol around $1,000-$1,400, varying by dose/insurance.[7] No generic versions exist for either. Patent expiry: stiripentol's key U.S. patents end 2026-2031; fenfluramine's around 2033 (check DrugPatentWatch.com for updates).[8][9]
When Might Doctors Pick One Over the Other?
Choose stiripentol for patients avoiding cardiac monitoring or already on clobazam. Pick fenfluramine for easier dosing, less sedation, or non-clobazam regimens. Long-term data favors fenfluramine for sustained efficacy up to 3 years.[10]
Sources
[1] NEJM: Stiripentol Trial (2000)
[2] Lancet Neurol: Fenfluramine Phase 3 (2018)
[3] Epilepsia: Fenfluramine Long-Term (2020)
[4] Cochrane Review: Dravet Treatments (2022)
[5] FDA Diacomit Label
[6] FDA Fintepla Label
[7] GoodRx Pricing Data (2023)
[8] DrugPatentWatch: Stiripentol
[9] DrugPatentWatch: Fenfluramine
[10] Epilepsy Behav: Fenfluramine 3-Year Data (2022)